Aurealis Therapeutics is a Swiss-Nordic Cell and Gene Therapy Platform Company.
Our multi-target Bacterial Vector therapy platform, based on genetically modified lactic bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers - Cancers - Ovarian, Peritoneal
Products, services, technology
Cooperation possibilities
2022: first licensing agreement for AUP-16 in China, for a total deal value of $139M plus royalties. We now have an IND approval for a Phase-2 study on Diabetic Foot Ulcers to be conducted in China.
We are aiming for a global licensing agreement - or multiple regional licensing - for AUP-16.
Some insights
We are a Cell and Gene Therapy Platform Company with positive Phase-2 data. Our multi-targeting products, based on genetically modified safe lactic acid bacteria, address broad unmet medical needs: Chronic Wounds - diabetic foot ulcers, venous ulcer - Ovarian Cancer, Inflammatory diseases.